menu
    • menu
    [{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Bain Capital Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"PDE9","graph1":"Cardiology\/Vascular Diseases","graph2":"Discovery","graph3":"Cardurion Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intramyocardial","sponsorNew":"Cardurion Pharmaceutical \/ Bain Capital Life Sciences","highestDevelopmentStatusID":"2","companyTruncated":"Cardurion Pharmaceutical \/ Bain Capital Life Sciences"},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"CRD-740","moa":"PDE9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Cardurion Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Cardurion Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Cardurion Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Cardurion Pharmaceutical","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"Tovinontrine","moa":"PDE9","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II","graph3":"Cardurion Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cardurion Pharmaceutical \/ Ascenta Capital","highestDevelopmentStatusID":"7","companyTruncated":"Cardurion Pharmaceutical \/ Ascenta Capital"}]

    Find Clinical Drug Pipeline Developments & Deals by Cardurion Pharmaceutical

    Menu

    Cardurion Pharmaceutical

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Cardurion Pharmaceutical

                            U.S.A arrow
                            Vietnam Medi Pharm
                            Not Confirmed

                            Cardurion Pharmaceutical

                            U.S.A arrow
                            Vietnam Medi Pharm
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tovinontrine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I/ Phase II

                            Sponsor : Ascenta Capital

                            Deal Size : $260.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Cardurion Raises $260M Series B Financing

                            Details : The Proceeds from the financing will be used to support late-stage clinical trials with the company’s lead drug candidates, which include a PDE9 inhibitor, CRD-750 (tovinontrine) for heart failure.

                            Product Name : CRD-750

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 16, 2024

                            Lead Product(s) : Tovinontrine

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Ascenta Capital

                            Deal Size : $260.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Cardurion Pharmaceutical

                            U.S.A arrow
                            Vietnam Medi Pharm
                            Not Confirmed

                            Cardurion Pharmaceutical

                            U.S.A arrow
                            Vietnam Medi Pharm
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CRD-740

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Cardurion Pharmaceuticals Announces Dosing of Patients in CARDINAL-HF, a Phase 2 Clinical Trial of its PDE9 in...

                            Details : CRD-740 is phosphodiesterase-9 (“PDE9”) inhibitor, the enzyme that metabolizes cardiac cGMP generated by the natriuretic peptide receptor (NPR) pathway ,for the treatment of heart failure.

                            Product Name : CRD-740

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 19, 2022

                            Lead Product(s) : CRD-740

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Cardurion Pharmaceutical

                            U.S.A arrow
                            Vietnam Medi Pharm
                            Not Confirmed

                            Cardurion Pharmaceutical

                            U.S.A arrow
                            Vietnam Medi Pharm
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Discovery

                            Sponsor : Bain Capital Life Sciences

                            Deal Size : $300.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Cardurion Pharmaceuticals Announces Investment of up to $300 Million From Bain Capital

                            Details : The investment will support the advancement of Cardurion’s pipeline of cardiovascular drug candidates includes a PDE9 inhibitor and a CaMKII inhibitor program, and enable the Company to scale its team, and create an industry-leading platform.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 27, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Discovery

                            Sponsor : Bain Capital Life Sciences

                            Deal Size : $300.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth